• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHAO Xu,TIAN Tian,GAO Lele,HONG Shuxia.Analysis of off-label drug use in hospitalized children with macrolide-resistant mycoplasma pneumoniae[J].Journal Of Pharmaceutical Research,2026,45(9):1072-1076[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 224times   Download 194次 QR Code for this article
Scan with your phone!
住院儿童大环内酯类耐药肺炎支原体感染的超药品说明书用药情况分析
赵旭1,田恬1,高乐乐2,洪术霞2
Font:Larger+|Default|Smaller-
(1.西安国际医学中心医院儿科,陕西 西安 710100;2.西安国际医学中心医院药学部,陕西 西安 710100)
摘要:
目的 回顾性分析大环内酯类耐药肺炎支原体(MRMP)感染住院患儿的超药品说明书用药情况,旨在为儿童超药品说明书用药管理提供参考依据旨在推动儿童用药规范,并为超药品说明书用药管理提供参考依据。方法 选取2023年1月至2024年12月陕西某三级综合医院妇女儿童院区儿科收治的164例重症MRMP感染患儿作为研究对象,对其大环内酯类耐药肺炎支原体感染超药品说明书用药使用情况进行收集与统计分析。结果 164例住院患儿年龄范围在7月~15岁,学龄前期及学龄期人群最多;超药品说明书用药品种涉及左氧氟沙星、多西环素、干扰素、布地奈德;超药品说明书用药主要类型为:超出适应证、超适应人群和超给药途径3类,其中超适应人群现象最为普遍。结论 大环内酯类耐药肺炎支原体感染的超药品说明书用药现象较为普遍存在,部分超药品说明书用药伴随着安全和法律风险,亟需规范此类用药行为。建议通过多学科协作规避用药风险,制定医院超药品说明书管理制度减少医疗纠纷,实现合理用药。
关键词:  儿童  左氧氟沙星  多西环素  大环内酯类耐药肺炎支原体  超药品说明书用药
DOI:10.13506/j.cnki.jpr.2026.09.017
基金项目:西安国际医学中心医院院级课题(No.2024QN06)
Received Date:December 26, 2025   Revision Date:April 15, 2026   Publication Date:September 30, 2026
Analysis of off-label drug use in hospitalized children with macrolide-resistant mycoplasma pneumoniae
ZHAO Xu1,TIAN Tian1,GAO Lele2,HONG Shuxia2
(1.Department of Pediatrics,Xi'an International Medical Center hospital,Xi'an 710100China;2.Department of Clinical Pharmacy,Xi'an International Medical Center, Xi'an 710100,China)
Abstract:
Objective To retrospectively analyze off-label drug use in pediatric inpatients with macrolide-resistant Mycoplasma pneumoniae(MRMP) infection, aiming to provide a reference for managing off-label drug use in pediatric patients. Methods A total of 164 pediatric patients admitted to the Pediatrics Department of the Women and Children's Hospital of a tertiary general hospital in Shaanxi Province from January 2023 to December 2024 were enrolled. Off-label drug use for macrolide-resistant Mycoplasma pneumoniae infection was collected and statistically analyzed. Results The 164 hospitalized patients comprised patients aged from 7 months to 15 years, with the highest prevalence among preschool and school-aged children. Off-label agents included levofloxacin, doxycycline, interferon, and budesonide. The primary categories of off-label drug use were: unapproved indications, unapproved patient populations, and unapproved routes of administration, with off-label drug use unapproved patient populations being the most prevalent. Conclusion Off-label drug use for macrolide-resistant Mycoplasma pneumoniae infections is prevalent. Certain off-label drug uses carry safety and legal risks, necessitating urgent regulation of such practices. Multidisciplinary collaboration is recommended to mitigate medication risks. Establishing institution-wide systems for regulating off-label drug use can reduce medical disputes and promote rational drug use.
Key words:  Children  Levofloxacin  Doxycycline  Macrolide-resistant Mycoplasma pneumoniae  Off-label drug use
Today's Visits:511    Total Visits:2383242
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.